Roche launches automated serology hepatitis E virus tests, including a test to detect acute HEV infections, recommended in the new WHO 2023 Essential Diagnostics List
- It is estimated that one third of the global population could be at risk for infection with Hepatitis E virus.1
- The new tests allow clinicians to diagnose acute and chronic infections amongst patients presenting with or without signs of the illness as recommended by the European Association for the Study of the Liver (EASL).2
- The tests complete Roche’s panel used for the differential diagnosis of acute viral hepatitis caused by the hepatitis A, B, C and E viruses.
Basel, 16 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the Elecsys®Anti-HEV IgM and Elecsys Anti-HEV IgG immunoassays for the detection of hepatitis E virus (HEV) infections in countries accepting the CE mark. By testing for HEV infection, clinicians can support their patients to identify the cause of their symptoms and determine appropriate treatment, monitor for progression to severe acute HEV and prevent severe disease progression with antiviral treatment.1,2,6
Recognising the value of diagnostics, the World Health Organization (WHO) has developed an “Essential Diagnostics List” which includes in-vitro diagnostics that should be available in all countries to increase timely and life-saving diagnoses. This year for the first time, tests for HEV are included to aid in the diagnosis and surveillance of HEV infection.5
“These tests highlight Roche’s commitment to contributing to the elimination of infectious diseases globally. Infection with HEV, a virus of significant global impact, results in 70,000 deaths and 3,000 stillbirths annually,”3,4 said Matt Sause, CEO of Roche Diagnostics. “The Anti-HEV IgM inclusion in the newly released WHO 2023 Essential Diagnostics List, demonstrates the important role this test plays in disease management for patients globally.
HEV testing also contributes to managing infected patients in high-risk groups and avoiding the misdiagnosis of drug-induced liver injury.1,2,6 They will also help to provide a more accurate estimate of the global HEV disease burden and inform governments and public health stakeholders on how to respond to the disease globally.5 As HEV is under-reported, the addition of these tests will support governments in managing outbreaks.
These fully automated assays will support lab personnel by enabling them to run them more efficiently compared to manual tests, as they require smaller sample volumes than manual tests, enabling results to be available within 18 minutes.
About the Elecsys Anti-HEV IgM and Anti-HEV IgG immunoassays
Elecsys Anti-HEV IgM is an immunoassay for the in vitro qualitative detection of IgM antibodies to HEV in human serum and plasma, and is used as an aid to detect an acute or recently acquired HEV infection. Elecsys Anti-HEV IgG is an immunoassay for the in vitro quantitative determination of IgG antibodies to HEV in human serum and plasma, and is used as an aid to detect a recent or past HEV infection.
The performance of both assays was evaluated in a multi-center study, which tested a total of more than 8,900 samples from presumed acute and recovered HEV infection for the determination of relative sensitivity, and from hospitalized patients, blood donors and pregnant women for the determination of relative specificity.
The overall relative sensitivity of the Elecsys Anti-HEV IgM and Elecsys Anti-HEV IgG assay was determined as 98.7% (95% CI 97.3 – 99.5%) and 99.1% (95% CI 98.0 – 99.7%), respectively. The overall specificity was determined as 99.4% (95% CI 99.2 – 99.6%) and 99.8% (95% CI 99.6 – 99.9%), respectively.
The new assays are available for use on the cobas® e 411 analyzer, cobas e 601/602 modules, and the cobas e 402 and cobas e 801 analytical modules. They expand Roche’s comprehensive viral hepatitis serology test portfolio, and complete the test panel used for the differential diagnosis of acute hepatitis caused by the hepatitis A, B, C and E viruses (alongside the Elecsys Anti-HAV IgM, Elecsys Anti-HBc IgM, Elecsys HBsAg II, Elecsys Anti-HCV II, and Elecsys HCV Duo assays).
About theWorld Health Organisation’s (WHO) 2023 Essential Diagnostics List (EDL)
The World Health Organisation’s (WHO) 2023 Essential Diagnostics List (EDL) is an evidence-based register of in vitro diagnostics that supports countries to make national diagnostic choices.
Updated biennially, the EDL is intended to support national in vitro diagnostics policy development and to improve access to IVD testing and clinical laboratory services. As well as informing national EDLs, it provides advice on prioritization of IVDs at different levels of the healthcare system. Additionally, it informs United Nations agencies and non-government organizations that support the selection, procurement, supply or donation of In Vitro Diagnostics along with guidance to the private health technology and manufacturing sectors about the IVDs priorities required to address global health issues.5
About hepatitis E virus (HEV)
HEV is a pathogen of growing global public health concern.7,8 HEV includes 8 genotypes, of which HEV-1 to 4 are the most frequently detected globally. HEV-1 and HEV-2 infect only humans, whereas HEV-3 and HEV-4 can infect both humans and animals such as pigs, wild boar, rabbits and deer.9-15 It is estimated that HEV-1 and HEV-2 account for approximately 20.1 million HEV infections, 3.4 million symptomatic cases, 70,000 deaths, and 3000 stillbirths annually.3
HEV-1 and HEV-2 are commonly found in developing countries with poor sanitation, where HEV is transmitted through the fecal-oral route.7,10, 16 HEV-3 accounts for most of the sporadic HEV infections in developed countries while HEV-4 is mainly found in Asia. Both HEV-3 and HEV-4 are transmitted zoonotically, most commonly through undercooked meat.7,17,18 In several countries, occasional transmission of HEV-3 and HEV-4 through blood transfusion has been reported.7, 19,20
HEV infection usually causes a mild or subclinical infection with a self-limiting illness that lasts from 2 to 6 weeks.21, 22 Symptomatic hepatitis E is similar to other acute hepatitis infections (fatigue, nausea, vomiting as well as jaundice and elevated liver enzymes).21 High-risk populations are immunocompromised patients (specifically transplant organ recipients),22,21,23,24 patients with underlying liver conditions, and elderly people and pregnant women.9,19,13,25-27
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
 Webb GW, Dalton HR. Hepatitis E: an underestimated emerging threat. Ther Adv Infect Dis. 2019;6:1-18
EASL. Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol 2018;68:1256-1271
 World Health Organization (WHO). Hepatitis E vaccine: WHO position paper. Wkly Epidemiol Rec. 2015;18:185-200.
 Rein DB, et al. The global burden of hepatitis E genotypes 1 and 2 in 2005. Hepatology. 2012;55:988-997.
 World Health Organization. WHO releases new list of essential diagnostics; new recommendations for hepatitis E virus tests, personal use glucose meters [Internet; updated 2023 Oct 19; cited Nov 2 2023]. Available from https://www.who.int/news/item/19-10-2023-who-releases-new-list-of-essential-diagnostics--new-recommendations-for-hepatitis-e-virus-tests--personal-use-glucose-meters
 Kar P, Karna RA. A Review of the Diagnosis and Management of Hepatitis E. Curr Treat Options Infect Dis 2020;12:310–320
 Khuroo MS, et al. Hepatitis E: Discovery, global impact, control and cure. World J Gastroenterol. 2016;22:7030-7045.
 Webb GW, Dalton HR. Hepatitis E: an underestimated emerging threat. Ther Adv Infect Dis. 2019;6:2049936119837162.
 Li P, et al. The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis. Liver Int. 2020;40(7):1516-1528.
 Goel A, Aggarwal R. Hepatitis E: Epidemiology, Clinical Course, Prevention, and Treatment. Gastroenterol Clin North Am. 2020;49:315-330.
 Raji YE, et al. Hepatitis E Virus: An emerging enigmatic and underestimated pathogen. Saudi J Biol Sci. 2022;29:499-512.
 Kamar N, et al. Hepatitis E. Lancet. 2012;379:2477-2488.
 Aggarwal R, Goel A. Natural History, Clinical Manifestations, and Pathogenesis of Hepatitis E Virus Genotype 1 and 2 Infections. Cold Spring Harb Perspect Med. 2019;9:a032136.
 Smith DB, et al. Update: proposed reference sequences for subtypes of hepatitis E virus (species Orthohepevirus A). J Gen Virol. 2020;101:692-698.
 Purdy MA, et al. ICTV Virus Taxonomy Profile: Hepeviridae. 2022. J Gen Virol 2022;103(9).
 Ruggeri FM, et al. Zoonotic transmission of hepatitis E virus in industrialized countries. New Microbiol. 2013;36:331-44.
 Izopet J, et al. Hepatitis E virus infections in Europe. J Clin Virol. 2019;120:20-26.
 World Health Organisation. Factsheet Hepatitis E. Last updated June 2022 [Internet, updated 2023 July, cited 2023 July 24]. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-e.
 Al-Sadeq DW, et al. Laboratory challenges in the diagnosis of hepatitis E virus. J Med Microbiol. 2018;67(4):466-480.
 Pérez-Gracia MT, et al. Hepatitis E: an emerging disease. Infect Genet Evol. 2014;22:40-59.
 Kamar N, et al. Hepatitis E virus infection. Nat Rev Dis Primers. 2017;3:17086.
 Lhomme S, et al. Hepatitis E Pathogenesis. Viruses. 2016;8:212.
 Larrue H, et al. Hepatitis E, what’s the real issue? Liver Int. 2020;40(Suppl 1):43-47.
 Lhomme S, et al. Risk of zoonotic transmission of HEV from rabbits. J Clin Virol. 2013;58:357-362.
 Zhao Q, et al. Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy. J Gastroenterol. 2013;48:159-168.
 Aggarwal R. Hepatitis E: clinical presentation in disease-endemic areas and diagnosis. Semin Liver Dis. 2013;33:30-40.
 Velavan TP, et al. Hepatitis E: An update on One Health and clinical medicine. Liver Int 2021;41:1462-1473.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: firstname.lastname@example.org
|Hans Trees, PhD|
Phone: +41 79 407 72 58
Phone: +41 79 771 05 25
Phone: +44 797 32 72 915
Phone: +41 79 461 86 83
Phone: +41 79 327 54 74
Phone: +49 172 6367262
|Dr. Rebekka Schnell|
Phone: +41 79 205 27 03
Phone: +41 79 935 81 48
Roche Investor Relations
|Dr. Bruno Eschli |
Phone: +41 61 68-75284
|Dr. Sabine Borngräber|
Phone: +41 61 68-88027
|Dr. Birgit Masjost|
Phone: +41 61 68-84814
|Dr. Gerard Tobin |
Phone: +41 61 68-72942
Investor Relations North America
Phone: +1 650 225 3217
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nokia Corporation Financial Calendar for 20241.12.2023 07:00:00 CET | Press release
Nokia Corporation Stock Exchange Release 1 December 2023 at 8:00 EET Nokia Corporation Financial Calendar for 2024 Espoo, Finland – In this stock exchange release, Nokia provides its financial calendar for 2024, which includes the planned publication dates of its financial reports. Planned publication dates for Nokia's financial reports in 2024: report for Q4 2023 and full year 2023: 25 January 2024report for Q1 2024: 18 April 2024report for Q2 2024 and half-year 2024: 18 July 2024report for Q3 2024 and January–September 2024: 17 October 2024 Publication of "Nokia in 2023" Nokia plans to publish its "Nokia in 2023" annual report, which includes the review by the Board of Directors and the audited annual accounts, during the week starting on 26 February 2024. Nokia's Annual General Meeting Nokia's Annual General Meeting 2024 is planned to be held on 3 April 2024. About Nokia At Nokia, we create technology that helps the world act together. As a B2B technology innovation leader, we are p
S&P Global Ratings raises its rating on CNH Industrial to ‘BBB+’1.12.2023 07:00:00 CET | Press release
Basildon, December 1, 2023 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that on November 30, 2023, S&P Global Ratings raised its long-term issuer credit ratings on CNH Industrial N.V. and its subsidiary, CNH Industrial Capital LLC, to 'BBB+' from 'BBB'. S&P Global Ratings also affirmed the 'A-2' short-term issuer credit rating. Additionally, S&P Global Ratings raised the issue-level ratings on CNH Industrial N.V. and its industrial subsidiaries' debt, as well as the issue-level ratings on CNH Industrial Capital LLC's senior unsecured debt, to 'BBB+' from 'BBB'. The outlook is stable. CNH Industrial (NYSE: CNHI / MI: CNHI) is a world-class equipment and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Productivity, the Company provides the strategic direction, R&D capabilities, and investments that enable the success of its global and regional Brands. Globally, Case IH and New Holland Agriculture supply 360° agricul
Canada Carbon Provides Update on Its Asbury Mine Exploration Program1.12.2023 04:04:42 CET | Press release
TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Canada Carbon Inc. (the "Company" or "Canada Carbon” or ("CCB"), (TSX-V:CCB), (FF:U7N1) is pleased to report that extensive graphitic mineralization was observed during its ongoing drill program on the Asbury Property (“the Property”). The Company would like to take this opportunity to provide a general update regarding the exploration program on the Property. Current exploration work includes drilling, completion of an NI 43-101 compliant resource calculation, metallurgical testing and development of a geochemical signature. The information provided from the exploration work will allow the Company to proceed with a Preliminary Economic Study to be completed in 2024. Drill Program Phase 1 of the drill program commenced on October 16th, and will be completed on November 30th 2023. The current drill program is testing a folded conductor anomaly, located on the North Eastern side of a regional magnetic anomaly. The drilled area is mostly located
Delårsrapport januari – september 202330.11.2023 23:59:00 CET | Pressemelding
Tredje kvartalet 2023 (jämfört med tredje kvartalet 2022) Nettoomsättningen uppgick till 8 MSEK (24)Bruttomarginalen ökade till 67 % (35 %)Rörelseresultatet ökade till 128 MSEK (-14)Periodens nettoresultat blev 122 MSEK (-4)Resultat per aktie före och efter utspädning ökade till 0,45 SEK (-0,05) Januari – september 2023 (jämfört med januari – september 2022) Nettoomsättningen uppgick till 30 MSEK (61)Bruttomarginalen ökade till 66 % (63 %)Rörelseresultatet ökade till 98 MSEK (-37)Nettoresultatet blev positivt och uppgick till 99 MSEK (-9)Resultat per aktie före och efter utspädning uppgick till 0,42 SEK (-0,17) Rapporten för januari – september 2023 i sin helhet finns tillgänglig på följande adress: https://www.anoto.com/investors/reports/ För ytterligare information kontakta: Joonhee Won, VD, Anoto Group AB För mer information om Anoto, besök www.anoto.com eller email email@example.com Denna information är sådan information som Anoto Group AB (publ) är skyldigt att offentliggöra enligt EU:
Interim Report January – September 202330.11.2023 23:59:00 CET | Press release
Third quarter 2023 (compared to third quarter 2022) Net sales for the quarter amounted to MSEK 8 (24)Gross margin for the quarter increased to 67% (35%)Operating profit increased to MSEK 128 (-14)Net income for the period turned to profit of MSEK 122 (-4)Earnings per share before and after dilution increased to SEK 0.45 (-0.05) January – September 2023 (compared to January – September 2022) Net sales for the period amounted to MSEK 30 (61)Gross margin for the period increased to 66% (63%)Operating profits increased to MSEK 98 (-37)Net income became positive at MSEK 99 (-9)Earnings per share before and after dilution increased to SEK 0.42 (-0.17) The report for January – September 2023 is available in its entirety on the following address: https://www.anoto.com/investors/reports/ For further information, please contact: Joonhee Won, CEO, Anoto Group AB For more information about Anoto, please visit www.anoto.com or email firstname.lastname@example.org This information is information that Anoto Group AB (